Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.04.2024 | Case report

Adalimumab/infliximab

Demyelination

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Sharma R, et al. DEMYELINATING DUO: TWO CASES DEMONSTRATING the SPECTRUM of TNF-a INHIBITOR-RELATED DEMYELINATION. BMJ Neurology Open 5: A38 abstr. 2704, No. 1, Aug 2023. Available from: URL: https://dx.doi.org/10.1136/bmjno-2023-ANZAN.103 Sharma R, et al. DEMYELINATING DUO: TWO CASES DEMONSTRATING the SPECTRUM of TNF-a INHIBITOR-RELATED DEMYELINATION. BMJ Neurology Open 5: A38 abstr. 2704, No. 1, Aug 2023. Available from: URL: https://dx.doi.org/10.1136/bmjno-2023-ANZAN.103
Metadaten
Titel
Adalimumab/infliximab
Demyelination
Publikationsdatum
01.04.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-55862-2

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Nivolumab

Case report

Baclofen

Case report

Multiple drugs

Case report

Prednisolone